Sanjivani Paranteral Ltd is a pharmaceutical company specializing in injectables and oral solid products. It operates two WHO-GMP certified manufacturing plants in Mumbai and Dehradun.

The company experienced a decline in revenue, EBITDA, and PAT, with a reported revenue of INR 155 mn for Q2 FY26, down 14.5% Y-o-Y.

Despite the revenue dip, Sanjivani maintains a significant export focus with 75% revenue coming from international markets, serving 25 countries globally.

The company has vast manufacturing capabilities, including a 720 million annual tablet capacity and 84 million annual ampoules capacity.

Sanjivani's planned capacity expansion with a new manufacturing plant at Taloja signals its foresight into scaling production for antibiotics and life-saving injectables.